Nuklearmedizin. Nuclear medicine最新文献

{"title":"The impact of the xSPECT reconstruction algorithms on the recovery coefficients value for small tumors: a phantom study with 177Lu.","authors":"Ali Ebrahimifard, Hossein Rajabi, Parham Geramifar, Markus Luster, Behrooz Hooshyar Yousefi, Robin de Nijs","doi":"10.1055/a-2418-2486","DOIUrl":"https://doi.org/10.1055/a-2418-2486","url":null,"abstract":"<p><p>Quantifying small tumors is still a challenge due to the partial volume effect (PVE). Although iterative reconstruction had promising results with a better recovery coefficient (RC), it suffers from the PVE. RC values typically depend on the reconstruction method, which may affect on ¹⁷⁷Lu quantifying. In this study, we investigated the effect of different reconstruction methods on RC values for ¹⁷⁷Lu SPECT/CT images.A water-filled cylindrical polymethylmethacrylate (PMMA) phantom without background radioactivity with two solid cylinders which represent the bone and soft tissue equivalent was used for SPECT/CT imaging. We placed syringes with different volumes containing ¹⁷⁷Lu in the vicinity of the cylinders as tumors. The iterative reconstructions of xSPECT, xSPECT Bone, and Flash3D was performed on SPECT/CT images.The effect of the reconstruction algorithms on the RC values was determined by calculating the radioactivity concentration in volumes of interest which were drawn manually and by a threshold method.The xSPECT Bone reconstruction has shown an RC value of approximately 100%, while the other reconstructions typically show an RC value of 93%. The RC values for all the reconstructions were decreased for smaller tumors. The smallest tumor showed a minimum RC between 52% and 72% compared to the largest tumor.In this study, it was possible to obtain an RC value close to 100% when the xSPECT Bone reconstruction algorithm was used. The xSPECT results were slightly lower RC values compared to the Flash3D algorithm. In using standard RC curves for tumors close to the bone, special care has to be taken since RC values relative to bone are higher than in tissue.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA - Targeted Clinical Molecular Imaging of Atherosclerosis: Correlation with Cardiovascular Risk Factors.","authors":"Julia K Baude, Felix M Mottaghy, Thorsten Derlin, Alexander Fischer, Alexander Heinzel, Jan Bucerius","doi":"10.1055/a-2390-2829","DOIUrl":"https://doi.org/10.1055/a-2390-2829","url":null,"abstract":"<p><strong>Aim: </strong>The early diagnosis of atherosclerotic changes to prevent ischemic events represents a clinical challenge.Prostate-specific membrane antigen (PSMA) as an established diagnostic in the field of prostate cancer also appears to detect neovascularization and inflammation in other diseases. We hypothesized that it might be also suited for detection of inflammation in atherosclerosis.</p><p><strong>Methods: </strong>We analyzed data of 78 prostate cancer patients who received a PSMA ligand PET/CT for re-staging. The cardiovascular risk factors (CVRF) of each patient were documented. Target-to-background-ratios (TBR) were calculated from the individual uptake values for three different sections of thoracic aorta [ascending (AA) and descending aorta (AD), aortic arch (AoAC)]. Statistical analyses included a linear regression analysis with the PSMA ligand uptake values of the different arterial segments versus different CVRF as independent variables.</p><p><strong>Results: </strong>The meanTBRmax was measured highest in the AoAC (1.66 ± 0.33) compared to both other vessel sections (AA: 1.46 ± 0.21, p=0.001; AD: 1.59 ± 0.41, p=0.371). There was a correlation between the PSMA ligand uptake in all measured segments of the aorta and BMI, but only a significant correlation in the ascending aorta (r=0.347, p=0.001). This was confirmed in a subgroup analysis, which showed significantly higher uptake values in preadiposity (BMI >25) and obesity (BMI >30) patients in the ascending aorta (p=0.048).</p><p><strong>Conclusion: </strong>PSMA ligand uptake in the ascending aorta was linked to BMI. PET detection of vascular PSMA ligand uptake may be indicative of vessel wall inflammation to some extent. However, PSMA ligands appear to be less suitable than other tracers for this purpose, given their absent correlation with most established CVRFs.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A metastatic melanoma with an atypical low 18F-FDG uptake.","authors":"Laura Ternoy, Pierre Meneret, Xavier Palard-Novello, David Russo","doi":"10.1055/a-2383-2584","DOIUrl":"https://doi.org/10.1055/a-2383-2584","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/CT Imaging and Hematological Parameters Can Help Predict HPV Status in Head and Neck Cancer.","authors":"Paulina Cegla, Geoffrey Currie, Joanna P Wroblewska, Joanna Kazmierska, Witold Cholewinski, Inga Jagiello, Krzysztof Matuszewski, Andrzej Marszalek, Anna Kubiak, Pawel Golusinski, Wojciech Golusinski, Ewa Majchrzak","doi":"10.1055/a-2365-7808","DOIUrl":"https://doi.org/10.1055/a-2365-7808","url":null,"abstract":"<p><strong>Objective: </strong>To determine whether [¹⁸F]FDG PET/CT and hematological parameters provide supportive data to determine HPV status in HNSCC patients.</p><p><strong>Methods: </strong>Retrospective analysis of clinical and diagnostic data from 106 patients with HNSCC: 26.4% HPV-positive and 73.6% HPV-negative was performed. The following semiquantitative PET/CT parameters for the primary tumor and hottest lymph node and liver were evaluated: SUV_max, SUV_mean, TotalSUV, MTV, TLG, maximum, mean and TLG tumor-to-liver ratio (TLR_max, TLR_mean,TLR_TLG) and heterogeneity index (HI). Following hematological variables were assessed: white blood cell (WBC); lymphocyte (LYMPH); neutrophil (NEU),monocyte (MON); platelet (PLT); neutrophil-to-lymphocyte ratio (NRL); lymphocyte-to-monocyte ratio (LMR); platelet-to lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR). Conventional statistical analyses were performed in parallel with an artificial neural network analysis (Neural Analyzer, v. 2.9.5).</p><p><strong>Results: </strong>Significant between-group differences were observed for two of the semiquantitative PET/CT parameters, with higher values in the HPV-negative group: primary tumor MTV (22.2 vs 9.65; p=0.023), and TLR_max (3.50 vs 2.46; p=0.05). The HPV-negative group also had a significantly higher NEU count (4.84 vs. 6.04; p=0.04), NEU% (58.2 vs. 66.2; p=0.007), and NRL% (2.69 vs. 3.94; p=0.038). Based on ROC analysis (sensitivity 50%, specificity 80%, AUC 0.5), the following variables were independent predictors of HPV-negativity: primary tumor with SUV_max >10; TotalSUV >2800; MTV >23.5; TLG >180; TLR_max >3.7; TLR_TLG >5.7; and oropharyngeal localization.</p><p><strong>Conclusion: </strong>Several semiquantitative parameters derived from [¹⁸F]FDG PET/CT imaging of the primary tumor (SUV_max, TotalSUV, MTV, TLG, TLR_max and TLR_TLG) were independent predictors of HPV-negativity.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 2D and 3D lung lobe quantification with Ventilation/Perfusion Ratio.","authors":"Julia Katharina Vogt, Wolfgang Kurt Vogt, Alexander Heinzel, Felix M Mottaghy","doi":"10.1055/a-2460-7254","DOIUrl":"https://doi.org/10.1055/a-2460-7254","url":null,"abstract":"<p><p>In this study, standard 2D lung lobe quantification is compared with two 3D lung lobe quantification software tools to investigate the clinical benefit of a 3D approach. The accuracy of 2D versus 3D lung lobe quantification is evaluated based on the calculated numerical ventilation-perfusion ratio (VQR) using a receiver operating curve (ROC) analysis.A study group of 50 consecutive patients underwent a planar lung scintigraphy (anterior/posterior) as well as ventilation/perfusion single photon emission computed tomography (SPECT/CT) to exclude acute pulmonary embolism. All data were acquired with SPECT OPTIMA NM/CT 640 (GE Healthcare). 2D analysis was performed for all ventilation/perfusion scans using a lung analysis tool (Syngo Workstation, Siemens Healthineers). 3D quantification analysis was performed using QLUNG (Q. Lung, Xeleris 4.0, GE Healthcare) and LLQ (Hermes Hybrid 3D Lung Lobar Quantification, Hermes Medical Solutions). The area under the ROC curve (AUC) served as a decision criterion to find the best agreement between clinical PE findings and calculated PE candidates of the 2D and 3D methods. The significance of the ROC curves was evaluated using the DeLong comparison.A significant difference between 2D/3D could be determined. Both 3D approaches showed robust and comparable results. The AUC range of [0.10, 0.67] was given for 2D lobar analysis, QLUNG AUC range revealed in [0.39,0.74] and LLQ AUC range was [0.42,0.72]. Averaged over all lung lobes an AUC=0.39 was given for 2D analysis and AUC=0.58 was given for LLQ/QLUNG.We could demonstrate the better performance of 3D analysis compared to 2D analysis. Consequently, is recommended to use a 3D approach in clinical practice.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid scintigraphy: establishing a clinically useful normal range for 99mTc pertechnetate uptake.","authors":"Michael Grunert, Simone Agnes Schenke, Andrea Konrad, Christina Schütze, Stefan Förster, Burkhard Klemenz, Alexander R Stahl","doi":"10.1055/a-2365-7917","DOIUrl":"10.1055/a-2365-7917","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to establish a normal range for the thyroid uptake derived from ^99mTc pertechnetate scans. In particular, variations of uptake with TSH stimulation and other factors such as urinary iodine concentration are taken into account and compared with the calculation of a raw uptake value.</p><p><strong>Methods: </strong>Clinical multicentric (center A, B and C) prospective study on 125 consecutive healthy patients undergoing thyroid scans for thyroid nodules. Normal functional thyroid status was assured by normal TSH, normal thyroid size, no thyroid antibodies and no symptoms of thyroid functional disorders. Calculations of raw Tc-uptake (uptake) and modified uptake values regarding current TSH value (uptake_TSH1), urinary iodine concentration (uptake_TSH1&uic), gland volume, age, smoking status, weight and tissue thickness ventral to the thyroid were performed.</p><p><strong>Results: </strong>There is a positive correlation of thyroid uptake with TSH allowing for the calculation of a normalized uptake value (uptake_TSH1). The normal range for uptake_TSH1 compares favourable to that for raw uptake in that it yields a clear distinction from thyroid functional disorders. The additional normalization for urinary iodine concentration (uptake_TSH1&uic) may even improve the distinctive power whereas further normalizations such as for gland volume, age and others are not warranted by this study. The 95% CI of uptake_TSH1 for sites A, A&B, and A&B&C were 0.21%-2.06%, 0.22%-2.38% and 0.24%-2.40%.</p><p><strong>Conclusion: </strong>A normal range for the thyroid uptake can be established with respect to the current TSH stimulation. This normalization (uptake_TSH1) overcomes the drawback of raw uptake by yielding a clinically useful parameter with obviously high distinctive power against functional thyroid disorders.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"337-346"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growing Teratoma Syndrome Revealed By F-18 FDG PET/CT.","authors":"Hatice Uslu, Dilruba Şahin, Mehmet Tarik Tatoglu, Ebru Ibisoglu","doi":"10.1055/a-2273-2350","DOIUrl":"10.1055/a-2273-2350","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"369-370"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Modern TARE 2023 - from palliative care to a curative treatment alternative].","authors":"Bernhard Gebauer, Federico Collettini, Christian Helmut Pfob, Constantin Lapa","doi":"10.1055/a-2353-5819","DOIUrl":"10.1055/a-2353-5819","url":null,"abstract":"<p><p>Selective internal radiotherapy (SIRT) or transarterial radioembolisation (TARE) is an alternative treatment for hepatocellular carcinoma (HCC) or hepatic metastatic colorectal carcinoma (mCRC) and is now anchored in many guidelines. The article summarises the current guidelines on SIRT/TARE in HCC and mCRC.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"328-336"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 8th and 7th editions of TNM staging in terms of mortality, persistent disease, and response to treatment in patients with differentiated thyroid cancer.","authors":"Golnaz Gholami, Atena Aghaee, Susan Shafiei, Bashir Rasoulian, Emran Askari, Samira Zare Namdar, Seyed Rasoul Zakavi","doi":"10.1055/a-2344-6638","DOIUrl":"10.1055/a-2344-6638","url":null,"abstract":"<p><strong>Objective: </strong>To compare the eighth and seventh editions of TNM staging (TNM-8 and TNM-7) on disease-related mortality, persistent disease, and response to treatment in patients with differentiated thyroid cancer (DTC).</p><p><strong>Methods and materials: </strong>We studied 400 patients (79% female) with DTC with a mean age of 40.93±14.11 years. TNM staging was recorded according to the 7th and 8th editions and patients were followed for at least 1 year and response to therapy was recorded according to ATA response categorization.</p><p><strong>Results: </strong>The mean follow up time was 42.5±15.24 months. Overall, 108 patients (27%) were down-staged using the TNM-8, mainly due to the changes in the age cut-off (14.5%), N (9.25%), and T categorization (3.25%). All patients in stage III and 82.8% in stage IV were down-staged. The mean Tg levels were significantly higher in stages III and IV in TNM-8 compared to TNM-7. Four disease-related death were recorded during follow up, all in stage IV according to TNM-7, while one was in stage II according to TNM-8. One year after treatment, persistent disease was detected in 12% and 77% of patients in stage III according to the 7th and 8th editions, respectively (P= 0.04). Similarly, biochemical incomplete response one year after treatment was seen in 7.3% and 87% in stage III disease using 7th and 8th editions (P = 0.006) that fell to 2.4% and 22% in the last visit respectively (P = 0.04).</p><p><strong>Conclusion: </strong>Persistent disease and incomplete response to therapy were more common in stages III and IV in TNM-8 compared to TNM-7. The eighth edition was a better predictor of persistent disease in stages III and IV disease.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"359-368"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy.","authors":"Esmail Jafari, Reyhaneh Manafi-Farid, Hojjat Ahmadzadehfar, Fatemeh Salek, Narges Jokar, Ahmad Keshavarz, GhasemAli Divband, Habibollah Dadgar, Farshad Zohrabi, Majid Assadi","doi":"10.1055/a-2365-8113","DOIUrl":"10.1055/a-2365-8113","url":null,"abstract":"<p><strong>Background: </strong>In this study, we sought to identify the clinical baseline characteristics and pre-therapy 68Ga-PSMA PET derived parameters that can have impact on PSA (biochemical) response, OS and PSA PFS in patients with metastatic castration-resistant prostate cancer (mCRPC) who undergo RLT with [177Lu]Lu-PSMA-617.</p><p><strong>Methods: </strong>Various pre-treatment clinical and PSMA PET derived parameters were gathered and computed. We used PSA response as the criteria for more than a 50% decrease in PSA level, and OS and PSA PFS as endpoints. We assessed the collected parameters in relation to PSA response. Additionally, we employed univariable Cox regression and Kaplan-Meier analysis with log rank to evaluate the influence of the parameters on OS and PFS.</p><p><strong>Results: </strong>A total of 125 mCRPC patients were included in this study. The median age was 68 years (range: 49-89). Among the cases, 77 patients (62%) showed PSARS, while 48 patients (38%) did not show PSA response. The median OS was 14 months (range: 1-60), and the median PSA-PFS was 10 months (range: 1-56). Age, prior history of chemotherapy, and SUVmax had a significant impact on PSA response (p<0.05). PSA response, RBC count, hemoglobin, hematocrit, neutrophil to lymphocyte ratio (NLR), alkaline phosphatase (ALP), number of metastases, wbPSMA-TV, and wbTL-PSMA significantly affected OS. GS, platelet count, NLR, and number of metastases were found to have a significant impact on PSA PFS.</p><p><strong>Conclusion: </strong>We have identified several baseline clinical and PSMA PET derived parameters that can serve as prognostic factors for predicting PSA response, OS, and PSA PFS after RLT. Based on the findings, we believe that these clinical baseline characteristics can assist nuclear medicine specialists in identifying RLT responders who have long-term survival and PFS.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"347-358"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}